Core Viewpoint - Huntsman reported a quarterly loss of $0.11 per share, aligning with the Zacks Consensus Estimate, but this reflects a deterioration from a loss of $0.06 per share a year ago [1] - The company’s revenues for the quarter were $1.41 billion, missing the Zacks Consensus Estimate by 4.68% and down from $1.47 billion year-over-year [2] Financial Performance - Huntsman has surpassed consensus EPS estimates two times over the last four quarters, but has only topped consensus revenue estimates once [2] - The company experienced a significant surprise in the previous quarter, with an expected loss of $0.12 per share turning into an actual loss of $0.25, resulting in a surprise of -108.33% [1] Stock Performance - Huntsman shares have declined approximately 26.2% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The current Zacks Rank for Huntsman is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $1.62 billion, while the estimate for the current fiscal year is -$0.05 on revenues of $6.21 billion [7] - The trend for earnings estimate revisions for Huntsman is currently unfavorable, which may impact future stock movements [6] Industry Context - The Chemical - Diversified industry, to which Huntsman belongs, is currently ranked in the bottom 16% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, emphasizing the importance of monitoring these changes [5]

Company Performance - Alphatec reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, representing an earnings surprise of -91.67% [1] - The company posted revenues of $169.18 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.23%, and showing an increase from $138.48 million year-over-year [2] - Over the last four quarters, Alphatec has not been able to surpass consensus EPS estimates, although it has topped consensus revenue estimates four times [2] Stock Outlook - Alphatec shares have increased by approximately 19.6% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $179.11 million, and for the current fiscal year, it is -$0.25 on revenues of $733.31 million [7] Industry Context - The Medical - Instruments industry, to which Alphatec belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Alphatec's stock performance [5]

Company Performance - Block reported quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.88 per share, and down from $0.85 per share a year ago, representing an earnings surprise of -36.36% [1] - The company posted revenues of $5.77 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 6.65%, and down from $5.96 billion year-over-year [2] - Over the last four quarters, Block has surpassed consensus EPS estimates just once and has not beaten consensus revenue estimates [2] Stock Performance - Block shares have lost about 31.2% since the beginning of the year, compared to the S&P 500's decline of -5.3% [3] - The current status of estimate revisions for Block is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $1 on $6.59 billion in revenues, and $4.12 on $26.06 billion in revenues for the current fiscal year [7] - The outlook for the industry can significantly impact the stock's performance, with the Internet - Software industry currently in the bottom 43% of Zacks industries [8]

Company Performance - iRhythm Technologies reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.89, but an improvement from a loss of $1.47 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $158.68 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.34% and showing an increase from $131.93 million in the same quarter last year [2] - Over the last four quarters, iRhythm Technologies has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - iRhythm Technologies shares have increased by approximately 18.5% since the beginning of the year, contrasting with a decline of 5.3% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.55 on revenues of $171.04 million, and for the current fiscal year, it is -$1.75 on revenues of $681.28 million [7] Industry Outlook - The Medical Info Systems industry, to which iRhythm Technologies belongs, is currently ranked in the top 18% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of iRhythm Technologies' stock may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Core Viewpoint - Standex International (SXI) reported quarterly earnings of $1.95 per share, exceeding the Zacks Consensus Estimate of $1.93 per share, and showing an increase from $1.75 per share a year ago, indicating a positive earnings surprise of 1.04% [1] Financial Performance - The company achieved revenues of $207.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.33%, compared to $177.27 million in the same quarter last year [2] - Over the last four quarters, Standex has consistently surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Stock Performance and Outlook - Standex shares have declined approximately 24.4% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $2.33 on revenues of $220.56 million, and for the current fiscal year, it is $7.86 on revenues of $785.88 million [7] - The estimate revisions trend for Standex is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Manufacturing - General Industrial industry, to which Standex belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Tarsus Pharmaceuticals reported a quarterly loss of $0.64 per share, which is better than the Zacks Consensus Estimate of a loss of $0.69, and an improvement from a loss of $1.01 per share a year ago, indicating a 36.6% year-over-year improvement [1] - The company achieved revenues of $78.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.06% and showing a significant increase from $27.61 million in the same quarter last year [2] - Tarsus Pharmaceuticals has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance relative to market expectations [2] Financial Performance - The company has shown an earnings surprise of 7.25% for the recent quarter and an 11.76% surprise in the previous quarter, reflecting positive momentum in earnings performance [1][2] - The current consensus EPS estimate for the upcoming quarter is -$0.38, with expected revenues of $86.76 million, while the estimate for the current fiscal year is -$1.22 on revenues of $361.17 million [7] Market Position - Tarsus Pharmaceuticals shares have underperformed the market with a decline of about 6.3% since the beginning of the year, compared to a decline of 5.3% for the S&P 500 [3] - The company holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future based on favorable estimate revisions [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Tarsus Pharmaceuticals belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Blueprint Medicines reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, representing an earnings surprise of -76.19% [1] - The company posted revenues of $149.41 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.04%, but showing an increase from $96.12 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $171.35 million, and for the current fiscal year, it is -$1.01 on revenues of $728.21 million [7] 分组2 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Blueprint Medicines shares have increased by approximately 2.6% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] - The estimate revisions trend for Blueprint Medicines is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Group 1 - PTC Inc. reported quarterly earnings of $1.79 per share, exceeding the Zacks Consensus Estimate of $1.38 per share, and up from $1.46 per share a year ago, representing an earnings surprise of 29.71% [1] - The company posted revenues of $636.37 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.62% and increasing from $603.07 million year-over-year [2] - PTC Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates three times in the same period [2] Group 2 - The stock has underperformed the market, losing about 16.4% since the beginning of the year compared to the S&P 500's decline of 5.5% [3] - The current consensus EPS estimate for the coming quarter is $1.46 on revenues of $623.14 million, and for the current fiscal year, it is $5.75 on revenues of $2.48 billion [7] - The Zacks Industry Rank for Computer - Software is in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Viewpoint - Qualcomm reported quarterly earnings of $2.85 per share, exceeding the Zacks Consensus Estimate of $2.83 per share, and showing an increase from $2.44 per share a year ago, indicating a positive earnings surprise of 0.71% [1][2] Financial Performance - The company achieved revenues of $10.84 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.55%, and up from $9.39 billion year-over-year [2] - Qualcomm has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Qualcomm shares have declined approximately 4.4% since the beginning of the year, while the S&P 500 has seen a decline of 5.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.65 on revenues of $10.29 billion, and for the current fiscal year, it is $11.85 on revenues of $43.39 billion [7] - The outlook for the Electronics - Semiconductors industry is positive, ranking in the top 23% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Etsy reported quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.50 per share, representing an earnings surprise of -8% [1]. Financial Performance - The company posted revenues of $651.18 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.33% and showing a year-over-year increase from $645.95 million [2]. - Over the last four quarters, Etsy has surpassed consensus revenue estimates three times [2]. Stock Performance - Etsy shares have declined approximately 12.8% since the beginning of the year, compared to a decline of -5.5% for the S&P 500 [3]. - The current consensus EPS estimate for the upcoming quarter is $0.52 on revenues of $638.28 million, and for the current fiscal year, it is $2.60 on revenues of $2.77 billion [7]. Industry Outlook - The Internet - Commerce industry, to which Etsy belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8]. - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Etsy's stock performance [5]. Future Expectations - The estimate revisions trend for Etsy is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]. - The upcoming earnings call will be crucial for assessing the sustainability of the stock's price movement based on management's commentary [3].